investor.amarincorp.comCompany Profile | Amarin Corporation plc

Skip to main navigation Skip to content Amarin Corporation Home About R&D Careers Investors FAQs Contact Amarin Corporation Home About R&D Careers Investors FAQs Contact You are about to review presentations, reports, filings and/or other materials regarding Amarin Corporation plc (NASDAQ: AMRN) that contain time-sensitive information. The information contained therein is only current as of the date thereof and may not be a complete listing of all documents filed with the Securities Exchange Commission, made public or provided to Amarin shareholders. Amarin expressly disclaims any obligation to review, update or correct these materials after the date thereof. Amarin may update, amend, supplement or otherwise alter the information contained in any such materials by subsequent presentations, reports, filings, or other means without notice. Certain statements made on this web site or in materials accessed in or through the investor relations section of our web site are "forward-looking statements," which are subject to risks and uncertainties, and Amarin's actual results may differ (possibly materially) from those indicated in such statements. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q. This website is not an offer or a solicitation to buy or sell securities. Please be aware that decisions regarding investments are the responsibility of users. Although this website includes information regarding pharmaceuticals (including products under development), the information is not intended as any advertisement and/or medical advice. This information is intended for communication with investors and should not be construed as marketing the use of any Amarin products or product candidates. Information on this website may be revised without any prior notice. Company Profile Investor Alert Amarin Receives FDA Approval of VASCEPA® (icosapent ethyl) to Reduce Cardiovascular Risk See press release here Updated Label information Company Profile Amarin Corporation plc. is a rapidly growing, innovative pharmaceutical company focused on developing therapeutics to improve cardiovascular health. Amarin’s product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa (icosapent ethyl) is Amarin's first FDA-approved drug and is available by prescription. For more information about Vascepa visit www.vascepa.com . The Company’s first drug, Vascepa (icosapent ethyl) is FDA-approved in the United States for treatment of patients with very high triglyceride levels (TG ≥500 mg/dL). The drug is also available by prescription in Lebanon and the United Arab Emirates. Amarin’s commercial partners are pursuing additional regulatory approvals for Vascepa in Canada, China and the Middle East and Amarin is evaluating potential commercial partnership arrangements for other countries while prioritizing promotion of Vascepa in the United States through Amarin’s sales team. In addition, the company has successfully completed a globally conducted, cardiovascular outcomes study with results which show that Vascepa lowers cardiovascular risk in patients with cardiovascular risk factors which cannot be addressed with cholesterol managing drugs alone. Amarin plans to seek expanded labeling for Vascepa to reflect the results of this outcomes study, called the REDUCE-IT study. Vascepa (icosapent ethyl) capsules are a single-molecule prescription product consisting of the omega-3 acid commonly known as EPA in ethyl-ester form. Vascepa is not fish oil, but is derived from fish through a stringent and complex FDA-regulated manufacturing process designed to effectively eliminate impurities and isolate and protect the single molecule active ingredient from degradation. Vascepa, known in scientific literature as AMR101, has been designated a new chemical entity by the FDA. Amarin has been issued multiple patents internationally based on the unique clinical profile of Vascepa, including the drug’s ability to lower triglyceride levels in relevant patient populations without raising LDL-cholesterol levels. For more information about Vascepa visit www.vascepa.com . For more information about Amarin visit www.amarincorp.com . If you are reporting an adverse event or product complaint, please email amarinmi@druginfo.com or call the Amarin Call Center at 1 855 VASCEPA. » See important safety information about Vascepa » See full prescribing information for Vascepa Amarin reported primary results of the successful REDUCE-IT trial concurrent with presentation of these results at the 2018 Scientific Sessions of the American Heart Association on November 10, 2018 in Chicago, Illinois. Results can be found in our press release . Additional references to such results are provided in a slide presentation of such results and in our results investor presentation . Amarin reported additional results of the successful REDUCE-IT trial at the American College of Cardiology’s 68th Annual Scientific Session. The press release on the data is here . Additional references to these results are provided in this slide presentation . Amarin is headquartered in Dublin, Ireland. In the U.S., the company's office is in Bedminster, New Jersey. Amarin is listed in the U.S. on NASDAQ (symbol: "AMRN"). Overview Title Documents February 2020 Investor Presentation Add Files February 2020 Investor Presentation 2.4 MB 38th Annual J.P. Morgan Healthcare Conference Add Links to Pages 38th Annual J.P. Morgan Healthcare Conference Amarin Receives FDA Approval of VASCEPA® (icosapent ethyl) to Reduce Cardiovascular Risk Add Links to Pages FDA Approval Webcast AHA Investor Webcast Add Links to Pages AHA Investor Webcast Press Releases Jan 13, 2020 Amarin Launches True To Your Heart, a Campaign to Educate People on Persistent Cardiovascular Risk Jan 07, 2020 Amarin Provides Update to Preliminary 2019 Results and Further Details on 2020 Outlook View All Home Menus Recent Updates Press Releases Events & Presentations Publications FAQS Corporate Governance The Board of Directors of Amarin Corporation plc (the "Company") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company's business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations. Title Documents Articles of Association Add Files Articles of Association 298.1 KB Memorandum and Articles of Association Add Files Memorandum and Articles of Association 298.1 KB Code of Business Conduct and Ethics Add Files Code of Business Conduct and Ethics 104.8 KB CA Declaration of Compliance 2019 Add Files CA Declaration of Compliance 2019 81.9 KB ADR List for 2020 Add Files ADR List for 2020 66.9 KB RELATED LINKS Executive Team Board Of Directors Annual Meeting Materials Filing date Form View Apr 25, 2019 DEF 14A View HTML 0001193125-19-117917.pdf 0001193125-19-117917.xls Apr 15, 2019 PRE 14A View HTML 0001193125-19-106686.pdf 0001193125-19-106686.xls View All Financial Information Here you will find a summary of Amarin Corporation plc's latest financial information. Latest Earnings Title Date Supporting Information Third Quarter Financial Results Nov 5, 2019 Quarterly Results Latest Annual Report Form Filing date View 10-K Feb 27, 2...